根據發(fa)行安(an)排，3只科創(chuang)板新股即(ji)將(jiang)發(fa)行。1月(yue)4日發(fa)行的是浩歐博；1月(yue)5日發(fa)行的是天能股份；1月(yue)6日發(fa)行的是之江生物。即(ji)將(jiang)發(fa)行的這3只新股合計預計募資67.84億(yi)元。

　　浩歐博(bo)，發(fa)(fa)(fa)行(xing)日期(qi)為(wei)1月(yue)4日，申(shen)購(gou)代碼(ma)為(wei)787656，擬公開發(fa)(fa)(fa)行(xing)股(gu)(gu)票1576.46萬(wan)(wan)(wan)股(gu)(gu)，其中(zhong)網上(shang)發(fa)(fa)(fa)行(xing)401.95萬(wan)(wan)(wan)股(gu)(gu)，發(fa)(fa)(fa)行(xing)價格為(wei)35.26元 ，發(fa)(fa)(fa)行(xing)市盈率為(wei)36.42倍，單一賬戶申(shen)購(gou)上(shang)限為(wei)0.40萬(wan)(wan)(wan)股(gu)(gu)，申(shen)購(gou)數(shu)量為(wei)500股(gu)(gu)的整數(shu)倍，頂格申(shen)購(gou)需持有滬市市值(zhi)4.00萬(wan)(wan)(wan)元。主營(ying)業(ye)務為(wei)專業(ye)從事體外(wai)診斷試(shi)劑(ji)的研發(fa)(fa)(fa)、生產和銷售。所屬行(xing)業(ye)為(wei)醫藥制造業(ye)，2018年、2019年凈利潤分別為(wei)4015.44萬(wan)(wan)(wan)元、6383.85萬(wan)(wan)(wan)元，同(tong)比變動幅度為(wei)88.04%、58.98%。

　　天能(neng)(neng)股(gu)(gu)份(fen)，發(fa)(fa)行(xing)(xing)日期為(wei)(wei)1月(yue)5日，申購代碼為(wei)(wei)787819，擬公(gong)開發(fa)(fa)行(xing)(xing)股(gu)(gu)票1.17億(yi)股(gu)(gu)，其中(zhong)網上(shang)發(fa)(fa)行(xing)(xing)2070.00萬(wan)股(gu)(gu)，發(fa)(fa)行(xing)(xing)價格為(wei)(wei)41.79元 ，發(fa)(fa)行(xing)(xing)市(shi)(shi)(shi)盈率(lv)為(wei)(wei)30.98倍，單一賬戶申購上(shang)限為(wei)(wei)2.05萬(wan)股(gu)(gu)，申購數量(liang)為(wei)(wei)500股(gu)(gu)的整數倍，頂格申購需持有滬市(shi)(shi)(shi)市(shi)(shi)(shi)值20.50萬(wan)元。公(gong)司(si)是一家以電(dian)(dian)(dian)動(dong)(dong)(dong)輕型(xing)車動(dong)(dong)(dong)力(li)電(dian)(dian)(dian)池(chi)(chi)業(ye)務為(wei)(wei)主,集電(dian)(dian)(dian)動(dong)(dong)(dong)特種(zhong)車動(dong)(dong)(dong)力(li)電(dian)(dian)(dian)池(chi)(chi)、新能(neng)(neng)源汽車動(dong)(dong)(dong)力(li)電(dian)(dian)(dian)池(chi)(chi)、汽車起動(dong)(dong)(dong)啟停電(dian)(dian)(dian)池(chi)(chi)、儲能(neng)(neng)電(dian)(dian)(dian)池(chi)(chi)、3C電(dian)(dian)(dian)池(chi)(chi)、備用(yong)電(dian)(dian)(dian)池(chi)(chi)等多品類電(dian)(dian)(dian)池(chi)(chi)的研發(fa)(fa)、生產、銷售為(wei)(wei)一體的國內電(dian)(dian)(dian)池(chi)(chi)行(xing)(xing)業(ye)領先企(qi)業(ye)之(zhi)一。 所屬(shu)行(xing)(xing)業(ye)為(wei)(wei)電(dian)(dian)(dian)氣機械和器材制造業(ye)，2018年、2019年凈利潤分(fen)別為(wei)(wei)12.17億(yi)元、14.92億(yi)元，同比變(bian)動(dong)(dong)(dong)幅度(du)為(wei)(wei)8.43%、22.55%。

　　之江(jiang)生物，發行日期為(wei)(wei)1月(yue)6日，申購(gou)代碼為(wei)(wei)787317，擬公開發行股(gu)票4867.61萬股(gu)，預計募資13.56億(yi)元，其中(zhong)網上(shang)發行1241.20萬股(gu)。主營業務為(wei)(wei)分(fen)子(zi)診斷試劑及儀(yi)器設備的研發、生產和銷售。所屬行業為(wei)(wei)醫藥制造(zao)業，2018年、2019年凈利潤分(fen)別(bie)為(wei)(wei)6231.85萬元、5152.18萬元，同比變動(dong)幅度(du)為(wei)(wei)20.93%、-17.33%。（數據(ju)寶）